

(Albany, US) DelveInsight’s "Dyspnea Market Insights, Epidemiology, and Market Forecast-2032" report provides an in-depth understanding of the disease, historical and forecasted epidemiology, as well as Dyspnea market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. To gather the best of the prospects and estimate the underlying potential of the Dyspnea market, the Report also examines current Dyspnea treatment practice/algorithm, market drivers, market barriers, and unmet medical requirements.
Some of the key facts of the Dyspnea market
- The worldwide dyspnea treatment market is being driven by an increase in the prevalence of dyspnea among the population as a result of an increase in causative symptoms such as COPD and asthma.
- The prevalence of dyspnea is considered to be high, with over 25% patients affected worldwide.
- According to DelveInsight, the Dyspnea market in 7MM is expected to change in the study period 2019-2032 due to increased illness awareness and incremental healthcare spending around the world, allowing medication makers to expand their market penetration.
- The most common diagnoses among older adult patients presenting to an ED with a complaint of acute shortness of breath and manifesting signs of respiratory distress (eg, respiratory rate >25, oxygen saturation [SpO2] <93 percent) are decompensated heart failure, pneumonia, chronic obstructive pulmonary disease (COPD), pulmonary embolism (PE), and asthma
- A chief complaint of dyspnea or shortness of breath accounts for 3.4 million visits (2.4 percent) of the more than 145 million visits to United States EDs in 2016.
Interested in knowing how the Dyspnea Market will be growing by 2032? Click to get a snapshot here: https://www.delveinsight.com/report-store/dyspnea-market
Dyspnea Overview
Dyspnea or shortness of breath is often described as an intense tightening in the chest, air hunger, difficulty breathing, breathlessness or a feeling of suffocation. Strenuous exercises, extreme temperatures, obesity and higher altitude all can cause shortness of breath in a healthy person. However, it could be a sign of a serious underlying health issue such as heart failure, chronic obstructive pulmonary disease (COPD), pneumonia, asthma, interstitial lung disease, allergies or anxiety.
The cause of shortness of breath is determined through-
- Physical exam
- Pulse oximetry
- Chest X-ray, CT scans or other special imaging test
- Blood test
- Lung function test, and
- Cardiopulmonary exercise testing
Based on the underlying condition, treatment for dyspnea include, exercising in order to improve physical health and strengthen heart and lungs, breathing techniques, medication such as bronchodilators, that help in relaxing air passage in cases of asthma and COPD, and oxygen therapy.
Key Companies in Dyspnea Market
- Mayne Pharma Group Limited
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline plc
- Bausch Health
- Hikma Pharmaceuticals plc
- Lannett Company, Inc.
- Amneal Pharmaceuticals LLC
- Mylan N.V.
- Lupin Limited
- Akron Incorporated
- ANI Pharmaceuticals, Inc.
- Pfizer, Inc.
- Sun Pharmaceutical Industries Ltd
Other Reports:
- Diagnostic Imaging Equipment Market
- Defibrillators Market
- Diagnostic Imaging Equipment Market
- Pulse Oximeters Market
- Achromatopsia Market
- Cataplexy Market
- Contusion Market
- Osteosarcoma Market
- Acute Lung Injury Market
- Intravenous Immunoglobulin Market
- Airway Stent Market
- Chronic Rhinosinusitis Phenotype with Nasal Polyps Market
- Neurostimulation Devices Market
- Capnography Devices Market
- Implantable Infusion Pumps Market
- Familial Primary Pulmonary Hypertension Market
- Giant Papillary Conjunctivitis Market
- Epithelioid Sarcoma Market





